CDA and pancreatic neoplasm: For example, overexpression of miR-608, which targets ribonucleotide reductase large subunit M1 (RRM1) and cytidine deaminase (CDA), decreased the viability of the gemicitabine-resistant MIA-PaCa-RG4 and AsPC-RG2 pancreatic cancer cells (Rajabpour et al., 2017).